These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 31179526)

  • 1. Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis.
    Ogawa Y; Takahashi N; Kaneko A; Hirano Y; Kanayama Y; Yabe Y; Oguchi T; Fujibayashi T; Takagi H; Hanabayashi M; Funahashi K; Hayashi M; Tsuboi S; Asai S; Asai N; Matsumoto T; Sobue Y; Ishiguro N; Kojima T
    Clin Rheumatol; 2019 Oct; 38(10):2757-2763. PubMed ID: 31179526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis.
    Gottenberg JE; Courvoisier DS; Hernandez MV; Iannone F; Lie E; Canhão H; Pavelka K; Hetland ML; Turesson C; Mariette X; Finckh A
    Arthritis Rheumatol; 2016 Jun; 68(6):1346-52. PubMed ID: 26815727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy predictors of a second tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis.
    Reams J; Berger A; Denio A
    Medicine (Baltimore); 2020 Aug; 99(35):e21827. PubMed ID: 32871905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
    Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
    Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
    Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
    Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
    Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry.
    Lin CT; Huang WN; Tsai WC; Chen JP; Hung WT; Hsieh TY; Chen HH; Hsieh CW; Lai KL; Tang KT; Tseng CW; Chen DY; Chen YH; Chen YM
    PLoS One; 2021; 16(4):e0250877. PubMed ID: 33930048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
    Kavanaugh A; Lee SJ; Curtis JR; Greenberg JD; Kremer JM; Soto L; Etzel CJ; Cox V; Yoshida K; Reed GW; Solomon DH
    Ann Rheum Dis; 2015 Jun; 74(6):1150-5. PubMed ID: 25471471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis.
    Petro AD; Dougherty J; England BR; Sayles H; Duryee MJ; Hunter CD; Kremer JM; Pappas DA; Robinson WH; Curtis JR; Thiele GM; Mikuls TR
    Int Immunopharmacol; 2021 Feb; 91():107260. PubMed ID: 33360371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.
    Jinno S; Onishi A; Dubreuil M; Hashimoto M; Yamamoto W; Murata K; Takeuchi T; Kotani T; Maeda Y; Ebina K; Son Y; Amuro H; Hara R; Katayama M; Saegusa J
    Arthritis Res Ther; 2021 Apr; 23(1):116. PubMed ID: 33858490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of individual autoantibodies, autoantibody combinations and levels for arthritis development in clinically suspect arthralgia.
    Ten Brinck RM; van Steenbergen HW; van Delft MAM; Verheul MK; Toes REM; Trouw LA; van der Helm-van Mil AHM
    Rheumatology (Oxford); 2017 Dec; 56(12):2145-2153. PubMed ID: 28968865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.
    Katchamart W; Koolvisoot A; Aromdee E; Chiowchanwesawakit P; Muengchan C
    Rheumatol Int; 2015 Oct; 35(10):1693-9. PubMed ID: 25903353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of biologic therapy due to lack/loss of response and adverse events is similar between TNFi and non-TNFi class: Results from a real-world rheumatoid arthritis cohort.
    Movahedi M; Hepworth E; Mirza R; Cesta A; Larche M; Bombardier C
    Semin Arthritis Rheum; 2020 Oct; 50(5):915-922. PubMed ID: 32911288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatoid factor as predictor of response to treatment with anti-TNF alpha drugs in patients with rheumatoid arthritis: Results of a cohort study.
    Santos-Moreno P; Sánchez G; Castro C
    Medicine (Baltimore); 2019 Feb; 98(5):e14181. PubMed ID: 30702571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of cumulative anti-cyclic citrullinated protein antibodies with radiographic progression in patients with rheumatoid arthritis.
    Joo YB; Park YJ; Park KS; Kim KJ
    Clin Rheumatol; 2019 Sep; 38(9):2423-2432. PubMed ID: 31049760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
    Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
    J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
    Lauper K; Mongin D; Iannone F; Kristianslund EK; Kvien TK; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Codreanu C; Lukina G; Gale SL; John M; Luder Y; Courvoisier DS; Gabay C
    Semin Arthritis Rheum; 2020 Feb; 50(1):17-24. PubMed ID: 31280937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials.
    Aletaha D; Alasti F; Smolen JS
    Arthritis Res Ther; 2015 Aug; 17(1):229. PubMed ID: 26307354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longterm retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapy.
    Matsubara H; Kojima T; Kaneko A; Hirano Y; Ishikawa H; Hattori Y; Miyake H; Oguchi T; Takagi H; Yabe Y; Kato T; Ito T; Fukaya N; Kanayama Y; Shioura T; Hayashi M; Fujibayashi T; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Terabe K; Ishiguro N
    J Rheumatol; 2014 Aug; 41(8):1583-9. PubMed ID: 25028370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries.
    Courvoisier DS; Chatzidionysiou K; Mongin D; Lauper K; Mariette X; Morel J; Gottenberg JE; Bergstra SA; Suarez MP; Codreanu C; Kvien TK; Santos MJ; Pavelka K; Hetland ML; Askling J; Turesson C; Kubo S; Tanaka Y; Iannone F; Choquette D; Nordström DC; Rotar Z; Lukina G; Gabay C; Van Vollenhoven R; Finckh A
    Rheumatology (Oxford); 2021 Feb; 60(2):820-828. PubMed ID: 32810263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.